FDA
-
-
-
-
-
-
-
Pacira BioSciences defends patent strategy amid proxy fight
-
-
-
-
-
-
-
Pacira BioSciences reports $726.4 million revenue for 2025
-
-
-
-
-
-
-
Pacira BioSciences Reports Third Quarter 2025 Financial Results; Increases Full-year Gross Margin Guidance
-
-
-
-
-
-
-
Pacira BioSciences Notified of Abbreviated New Drug Application Filing from The WhiteOak Group for EXPAREL®
-
-
-
-
-
-
-
Pacira BioSciences (PCRX) Presents New Data on the Effects of Clinical Immunogenicity on Locally Administered PCRX-201 in Patients with Moderate to Severe Osteoarthritis of the Knee
-
-
-
-
-
-
-
Pacira BioSciences (PCRX) Announces First Patient Dosed in Phase 2 Study Evaluating Safety and Efficacy of PCRX-201 for the Treatment of Osteoarthritis of the Knee
-
-
-
-
-
-
-
Pacira Announces New Five-Year Objectives to Accelerate Transition into an Innovative Biopharmaceutical Organization
-
327,071 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

